Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Declercq J (COV-AID)
 
NCT04330638
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
114/115 inconclusive 2%
RCT-TCZ-COVID-19
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive 112%
RECOVERY
 
NCT04381936
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
2022/2094 conclusif demonstrated-13% -13%
Rutgers RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
174/180 suggested -34% -32%
Soin AS (COVINTOC)
 
CTRI/2020/05/025369
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
90/90 inconclusive -30%
Dongsheng Wang
 
ChiCTR2000029765
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
33/32 safety concern 123%
EMPACTA
 
NCT04372186
RCTtocilizumab placeboCOVID 19 hospitalizedsome concern
259/129 conclusif 12% 13% demonstrated-40%
EU-CTR2020-001375-32 (PreToVid) unpublished
 
EU-CTR2020-001375-32
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
174/180 inconclusive -37%
EU-CTR2020-001748-24 (ImmCoVA) unpublished
 
EU-CTR2020-001748-24
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
22/27 inconclusive 23%
NCT04412772 (ARCHITECTS) unpublished
 
NCT04412772
RCTtocilizumab placeboCOVID 19 hospitalizedlow
10/11 inconclusive -74%
NCT04434717 (COVITOZ-1 single dose plus two doses) unpublished
 
NCT04434717
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
17/9 inconclusive -44%
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg) unpublished
 
NCT04479358
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
20/8 inconclusive -84%
NCT04577534 (COVIDSTORM) unpublished
 
NCT04577534
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
26/13 inconclusive -46%

COVID 19 all comers meta-analysis

BACC Bay Tocilizumab Trial
 
NCT04356937
RCTtocilizumab placeboCOVID 19 all comerslow
161/81 inconclusive 47% 5% -15%

COVID-19 severe or critically meta-analysis

MARIPOSA
 
NCT04363736
RCTtocilizumab tocilizumab COVID-19 severe or criticallysome concern
48/49 inconclusive
REMAP-CAP (tocilizumab)
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
Rosas (REMDACTA)
 
NCT04409262
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive -5% -2%
Talaschian
 
IRCT20081027001411N4
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive 23%
Veiga
 
NCT04403685
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern153% 49%
CORIMUNO-TOCI-1 (Group 1)
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
64/67 inconclusive -7% -39%
CORIMUNO-TOCI-ICU (Group 2)
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
49/43 inconclusive -32%
COVACTA (Rosas)
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 suggested 25% 17%
15 studies excluded by filtering options (4 RCT / 11 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).